NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
23:12
Houthi militias in Yemen attacked two Saudi oil tankers, Wafa and Daisy, in the Red Sea and the Gulf of Aden
22:55
The British Foreign Secretary avoids answering whether he still considers Donald Trump an "idiot," "racist," and "misogynist."
22:41
Armed attack with multiple victims in Prospect Hill, North Carolina
22:20
An explosive drone was found on the runway of the airport in Leipzig / The German police deployed a bomb disposal robot
21:47
Iran and Oman have agreed on a shipping route through the Strait of Hormuz
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
